Summary
This is a standards-of-care guideline from the American Diabetes Association's Professional Practice Committee, published in 2025, synthesising evidence on diagnosis, management and treatment of diabetes in pregnancy. The guideline provides clinical recommendations intended to optimise maternal glycaemic control and foetal outcomes, reflecting contemporary evidence on screening, diagnostic criteria, pharmacological and lifestyle interventions, and monitoring protocols for pregnant people with pre-existing or gestational diabetes.
UK applicability
UK clinical practice is governed by NICE guidelines, which may differ in specific diagnostic thresholds and treatment recommendations from the ADA standards. However, the evidence base regarding glycaemic targets, screening approaches and foetal outcomes is internationally relevant and likely informs or complements UK guidance.
Key measures
Diagnostic thresholds for GDM; glycaemic targets during pregnancy; insulin and medication recommendations; screening protocols; maternal and foetal outcomes
Outcomes reported
The paper presents clinical care standards and evidence-based recommendations for managing diabetes during pregnancy, including screening, diagnostic criteria, glycaemic targets, and treatment protocols. Standards address both gestational diabetes mellitus (GDM) and pre-existing diabetes in pregnant patients.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.